Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Takanori Hayasaki"'
Autor:
Takanori Ikeda, Satoshi Ogawa, Takanari Kitazono, Jyoji Nakagawara, Kazuo Minematsu, Susumu Miyamoto, Yuji Murakawa, Michiya Tachiiri, Yutaka Okayama, Toshiyuki Sunaya, Kazufumi Hirano, Takanori Hayasaki
Publikováno v:
Journal of Arrhythmia, Vol 38, Iss 3, Pp 369-379 (2022)
Abstract Background To evaluate the impact of three risk factors (age [≥75 years], renal impairment [creatinine clearance
Externí odkaz:
https://doaj.org/article/3201ca7d16c64b13a18f5be7effbc3a1
Autor:
Ikuo Fukuda, Atsushi Hirayama, Kazuo Kawasugi, Takao Kobayashi, Hideaki Maeda, Mashio Nakamura, Norifumi Nakanishi, Norikazu Yamada, Tsubasa Tajima, Sanghun Iwashiro, Yutaka Okayama, Toshiyuki Sunaya, Kazufumi Hirano, Takanori Hayasaki
Publikováno v:
TH Open, Vol 05, Iss 04, Pp e521-e532 (2021)
Background The efficacy and safety of rivaroxaban have been demonstrated in phase 3 trials of patients with venous thromboembolism (VTE; pulmonary embolism [PE] and deep vein thrombosis [DVT]). Data regarding rivaroxaban treatment of VTE in routine J
Externí odkaz:
https://doaj.org/article/313ff2ce01f142e49eb686e8b2f02342
Autor:
Takanori Ikeda, Satoshi Ogawa, Takanari Kitazono, Jyoji Nakagawara, Kazuo Minematsu, Susumu Miyamoto, Yuji Murakawa, Sanghun Iwashiro, Yutaka Okayama, Toshiyuki Sunaya, Kazufumi Hirano, Takanori Hayasaki
Publikováno v:
PLoS ONE, Vol 16, Iss 6, p e0251325 (2021)
BackgroundThe Xarelto Post-Authorization Safety and Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS) was designed to investigate safety and effectiveness during long-term follow-up of rivaroxaban treatment, using reduced dos
Externí odkaz:
https://doaj.org/article/b4c49a7ceb404b83a60b6d9e87b35dea
Autor:
Ikuo Fukuda, Atsushi Hirayama, Kazuo Kawasugi, Takao Kobayashi, Hideaki Maeda, Mashio Nakamura, Norikazu Yamada, Tsubasa Tajima, Michiya Tachiiri, Yutaka Okayama, Toshiyuki Sunaya, Kazufumi Hirano, Takanori Hayasaki
Publikováno v:
Circulation Journal.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e28ef04c9cd40342fa001f9b94c26ab6
https://doi.org/10.1253/circj.cj-23-0104
https://doi.org/10.1253/circj.cj-23-0104
Autor:
Norifumi Nakanishi, Kazuo Kawasugi, Takao Kobayashi, Atsushi Hirayama, Ikuo Fukuda, Mashio Nakamura, Tsubasa Tajima, Kazufumi Hirano, Norikazu Yamada, Yutaka Okayama, Sanghun Iwashiro, Hideaki Maeda, Takanori Hayasaki, Toshiyuki Sunaya
Publikováno v:
TH Open: Companion Journal to Thrombosis and Haemostasis
TH Open, Vol 05, Iss 04, Pp e521-e532 (2021)
TH Open, Vol 05, Iss 04, Pp e521-e532 (2021)
Background The efficacy and safety of rivaroxaban have been demonstrated in phase 3 trials of patients with venous thromboembolism (VTE; pulmonary embolism [PE] and deep vein thrombosis [DVT]). Data regarding rivaroxaban treatment of VTE in routine J
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bb5ea6c535f8420d609fec71895615f
http://europepmc.org/articles/PMC8639284
http://europepmc.org/articles/PMC8639284
Autor:
Takanori Hayasaki, Yoshimi Matsuda, Yasuhiro Hayashi, Kiyoshi Nobori, Hiroyasu Yamamoto, Tadao Akizawa, Takashi Yamada
Publikováno v:
Kidney International Reports
Introduction Molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor for renal anemia treatment, was evaluated in 5 phase 3 studies (MIYABI program). We report the results of the MIYABI hemodialysis-maintenance study. Methods This 52-week
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54d800c748ba340ad4ed168070ccbb35
http://europepmc.org/articles/PMC8484124
http://europepmc.org/articles/PMC8484124
Publikováno v:
Circulation journal : official journal of the Japanese Circulation Society. 86(7)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e89fb0d193fd3164a98dc923e02c6cc
https://pubmed.ncbi.nlm.nih.gov/35644538
https://pubmed.ncbi.nlm.nih.gov/35644538
Autor:
Takanori Hayasaki, Kiyoshi Nobori, Yoshimi Matsuda, Tadao Akizawa, Hiroyasu Yamamoto, Yasuhiro Hayashi
Publikováno v:
American Journal of Nephrology. 52:871-883
Introduction: Molidustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that predominantly induces renal production of erythropoietin (EPO). Molidustat was evaluated for the treatment of anemia associated with chronic kidney disease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::79f057e83db8456ed76e29895d0af259
https://doi.org/10.1159/000518071
https://doi.org/10.1159/000518071
Autor:
Yasuhiro Hayashi, Tadao Akizawa, Hiroyasu Yamamoto, Yoshimi Matsuda, Takanori Hayasaki, Kiyoshi Nobori
Publikováno v:
American Journal of Nephrology. 52:884-893
Introduction: Erythropoiesis-stimulating agents (ESAs) are the current standard of care for anemia due to chronic kidney disease (CKD) in patients not undergoing dialysis. Molidustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e42b9ed5f9f0df79fbe2fa870e7e29c6
https://doi.org/10.1159/000518072
https://doi.org/10.1159/000518072
Autor:
Hiroyasu Yamamoto, Kentaro Taki, Yasuhiro Hayashi, Kiyoshi Nobori, Yoshimi Matsuda, Takanori Hayasaki, Tadao Akizawa
Publikováno v:
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. 26(2)
This 36-week, open-label, single-arm, phase 3 study investigated the safety and efficacy of molidustat in Japanese patients with renal anemia undergoing peritoneal dialysis. Molidustat was titrated every 4 weeks to maintain Hb levels within the targe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ff381749029ed4eb3ba2c8760d27ca7
https://pubmed.ncbi.nlm.nih.gov/34310049
https://pubmed.ncbi.nlm.nih.gov/34310049